Works matching IS 00302414 AND DT 2023 AND VI 101 AND IP 11
Results: 9
Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 738, doi. 10.1159/000533303
- By:
- Publication type:
- Article
Front & Back Matter.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 1, doi. 10.1159/000534780
- Publication type:
- Article
Postoperative Early Body Weight Loss Is a Risk Factor for Recurrence in Patients with pStage III Gastric Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 705, doi. 10.1159/000532089
- By:
- Publication type:
- Article
The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 695, doi. 10.1159/000532087
- By:
- Publication type:
- Article
Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 730, doi. 10.1159/000531870
- By:
- Publication type:
- Article
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 723, doi. 10.1159/000531722
- By:
- Publication type:
- Article
Circulating Cell-Free DNA as a Biomarker for Prognosis and Response to Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 714, doi. 10.1159/000531671
- By:
- Publication type:
- Article
Lower Body Mass Index and Prognostic Nutritional Index Are Associated with Poor Posttransplant Outcomes in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 753, doi. 10.1159/000531576
- By:
- Publication type:
- Article
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
- Published in:
- Oncology, 2023, v. 101, n. 11, p. 685, doi. 10.1159/000530809
- By:
- Publication type:
- Article